Safety and efficacy of autoantigen‐specific therapy with 2 doses of alum‐formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Treatments have failed to delay or stop the autoimmune process, preceding onset of type 1 diabetes. We investigated if autoantigen-specific treatment with alum-formulated glutamate decarboxylase (GAD-Alum) was safe and affected progression to type 1 diabetes in children with islet autoimmunity. METHODS: In an investigator-initiated, double-blind, placebo-controlled clinical trial, non-diabetic children aged 4 to 17.9 years with autoantibodies to glutamate decarboxylase (GADA) and at least one of insulinoma-associated protein 2, insulin or zinc-transporter 8, were randomized, stratified by 2 or ≥3 islet autoantibodies, to 2 injections of 20 μg GAD-Alum or placebo, 30 days apart. Main outcome was safety, investigated by adverse events, hematology, chemistry, thyroid and celiac autoimmunity and titers of islet autoantibodies, and efficacy, investigated by cumulative incidence of diabetes onset over 5-year follow-up. Secondary variables: change in first-phase insulin release (FPIR) after intravenous glucose tolerance tests, fasting, 120 minutes and Area under the curve (AUC) C-peptide and p-glucose after oral glucose tolerance tests and HbA1c. RESULTS: Fifty children (median age: 5.2) were assigned 1:1 to GAD-Alum or placebo, all receiving full treatment and included in the analyses. GAD-Alum did not affect any safety parameter, while GADA titers increased (P = .001). Time to clinical diagnosis was not affected by treatment (hazard ratio, HR = 0.77, P = .574) in the full population or in the separate stratum groups. Treatment did not affect any of the secondary variables. CONCLUSIONS: GAD-Alum as a subcutaneous prime and boost injection was safe in prediabetic young children but did not affect progression to type 1 diabetes. The safety of GAD-Alum should prove useful in future prevention studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children
Ziegler, A. G., Rewers, M., Simell, O., Simell, T., Lempainen, J., Steck, A., Winkler, C., Ilonen, J., Veijola, R., Knip, M., et al. (2013) · JAMA · doi:10.1001/jama.2013.6285 · Cited by 1,312
Effects of insulin in relatives of patients with type 1 diabetes mellitus
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012350 · Cited by 836
Effects of Oral Insulin in Relatives of Patients With Type 1 Diabetes
The Diabetes Prevention Trial-Type 1 Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1068 · Cited by 668
Gale, E. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15786-3 · Cited by 534
GAD treatment and insulin secretion in recent-onset type 1 diabetes
Ludvigsson, J., Faresjö, M., Hjorth, M., Axelsson, S., Chéramy, M., Pihl, M., Vaarala, O., Forsander, G., Ivarsson, S., Johansson, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804328 · Cited by 520 · cited 2×
“Moreover, the 2 phase III studies in children(16,17) had not yet been evaluated, and the only dosing that had safety data in children was the prime and boost regimen used in the first phase II study.(15) Therefore, it was important to start in a small group, and with a dose proven safe in previous studies, when includ…”
BackgroundResultNäntö-Salonen, K., Kupila, A., Simell, S., Siljander, H., Salonsaari, T., Hekkala, A., Korhonen, S., Erkkola, R., Sipilä, J. I., Haavisto, L., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61309-4 · Cited by 382
Wherrett, D. K., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Marks, J. B., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60895-7 · Cited by 371
Self-citationGAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus
Ludvigsson, J., Krisky, D., Casas, R., Battelino, T., Castaño, L., Greening, J., Kordonouri, O., Otonkoski, T., Pozzilli, P., Robert, J.-J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107096 · Cited by 340
Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes
Agardh, C.-D., Cilio, C. M., Lethagen, Å., Lynch, K., Leslie, R. D. G., Palmér, M., Harris, R. A., Robertson, J. A., & Lernmark, Å. (2005) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2004.12.003 · Cited by 226
Cited by
Chung, W. K., Erion, K., Florez, J. C., Hattersley, A. T., Hivert, M.-F., Lee, C. G., McCarthy, M. I., Nolan, J. J., Norris, J. M., Pearson, E. R., et al. (2020) · Diabetes Care · doi:10.2337/dci20-0022 · Cited by 400
Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals
Sims, E. K., Bundy, B. N., Stier, K., Serti, E., Lim, N., Long, S. A., Geyer, S. M., Moran, A., Greenbaum, C. J., Evans-Molina, C., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc8980 · Cited by 377
Chung, W. K., Erion, K., Florez, J. C., Hattersley, A. T., Hivert, M.-F., Lee, C. G., McCarthy, M. I., Nolan, J. J., Norris, J. M., Pearson, E. R., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05181-w · Cited by 203
Changing the landscape for type 1 diabetes: the first step to prevention
Dayan, C. M., Korah, M., Tatovic, D., Bundy, B. N., & Herold, K. C. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32127-0 · Cited by 96
Zhao, L. P., Papadopoulos, G. K., Skyler, J. S., Parikh, H. M., Kwok, W. W., Bondinas, G. P., Moustakas, A. K., Wang, R., Pyo, C.-W., Nelson, W. C., et al. (2024) · Diabetes Care · doi:10.2337/dc24-0573 · Cited by 20
Metadata
- Authors
- Elding Larsson, H., Lundgren, M., Jonsdottir, B., Cuthbertson, D., Krischer, J., & for the DiAPREV‐IT Study Group
- Venue
- Pediatric Diabetes
- Publisher
- Wiley
- Published
- 2017-11-24
- Volume
- 19
- Issue
- 3
- Pages
- 410-419
- ISSN
- 1399-543X (ISSN-L)
- 1399-5448
- OpenAlex
- W2770523592
- Cited by
- 63
- References
- 10
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and efficacy of autoantigen‐specific therapy with 2 doses of alum‐formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial. https://app.cochat.ai/papers/10.1111/pedi.12611
- The paper
- Elding Larsson, H., Lundgren, M., Jonsdottir, B., Cuthbertson, D., Krischer, J., & for the DiAPREV‐IT Study Group. (2018). Safety and efficacy of autoantigen‐specific therapy with 2 doses of alum‐formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial. Pediatric Diabetes. https://doi.org/10.1111/pedi.12611
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.